by adminTorusBrand | Nov 8, 2016 | Axim Biotechnologies, Company News
Medical Marijuana, Inc. announced this week that AXIM® Biotechnologies secured the necessary private funding needed to continue its pharmaceutical clinical trials program in the development of cannabinoid medications for multiple medical indications. On news of AXIM®...
by adminTorusBrand | Nov 3, 2016 | Axim Biotechnologies, Media Coverage, Press Releases
Cannabinoid Innovator’s Product Pipeline Highlights Timelines of Its Intellectual Property (IP) Protected Cannabinoid-Based Products from Pre-Clinical to NDA for Multiple Indications NEW YORK – Nov. 3, 2016 – Medical Marijuana, Inc. (OTC: MJNA) today announced that...
by adminTorusBrand | Nov 1, 2016 | Axim Biotechnologies, Company News
[vc_row][vc_column][vc_column_text]The premier educational and networking event for investment professionals, the MoneyShow was created to address the concerns of modern investors. At this month’s MoneyShow Dallas, there was great interest surrounding the cannabis...
by adminTorusBrand | Nov 1, 2016 | Axim Biotechnologies, Press Releases
NEW YORK, NY –(Marketwired – November 01, 2016) – Medical Marijuana, Inc.(MJNA) today announced that its portfolio company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM) has begun pharmacokinetic/pharmacodynamics (PK/PD) studies with its CanChew...
by adminTorusBrand | Oct 26, 2016 | Axim Biotechnologies, Press Releases
Financing Enables Cannabinoid Innovator to Continue Phase I-II Trials Of Numerous Intellectual Property (IP) Protected Cannabinoid-Based Products NEW YORK – Oct. 26, 2016 – Medical Marijuana, Inc. (OTC: MJNA) today announced that its portfolio company AXIM®...
by adminTorusBrand | Oct 19, 2016 | Axim Biotechnologies, Company News
[vc_row][vc_column][vc_column_text]If there is a central issue holding back the expansion of legal medical cannabis in America, it is a perceived lack of research. It is the refrain rising up out of the throats of all opponents to cannabis legalization. Lack of...
